KAIROS PHARMA LTD (KAPA)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.84+10.18%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KAPA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KAPA — capital allocation
Dated 2026-08-21
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Why it matters: If the health care sector's revenue growth speeds up, it may help KAIROS too.
Supportive ifHealth care revenue growth speeds up to 9% or more.
Worry ifHealth care revenue growth keeps slowing down below current levels.
Why it matters: The reverse stock split aims to boost share price and maintain NYSE listing. If successful, it could attract more institutional investors.
Supportive ifKAPA shares trade above $5 on a split-adjusted basis after the reverse stock split.
Worry ifKAPA shares are under $5 after the split. This may lead to delisting from NYSE.
Why it matters: Good results would show that ENV-105 can help patients with hard-to-treat prostate cancer.
Supportive ifMedian progression-free survival exceeds 13 months in the Phase 2 trial for ENV-105.
Worry ifMedian progression-free survival is less than 13 months or does not improve much.
Why it matters: Revenue growth trends will show if KAIROS is improving or struggling in a tough market.
Watch forQ2 revenue growth is positive compared to last year. This shows recovery.
Also watch forQ2 revenue growth is still negative compared to last year. This shows ongoing struggles.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$361 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $951 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,854 loss on $10,000 · 88.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this trial shows Kairos wants to grow its lung cancer treatment options.
Supportive ifAnnouncement of the initiation of the Phase 1 study for CL-741.
Worry ifNo announcement of the Phase 1 study initiation by the end of 2026.
Why it matters: The partnership aims to boost ENV-105's effect in prostate cancer. Progress could show strong market potential.
Supportive ifKairos shares good early results from the partnership. They show better outcomes for prostate cancer patients.
Worry ifNo major progress or bad results were reported from the Bayer partnership in six months.
Why it matters: Revenue growth below median would signal a potential slowdown in the sector's growth phase.
Worry ifQ2 revenue growth reported below the median for the healthcare sector.
Less concerning ifQ2 revenue growth remains above the median for the healthcare sector.
Why it matters: Positive interim data could validate ENV-105's potential and drive interest in the stock. It is crucial for Kairos's growth strategy.
Supportive ifManagement shows early data. The clinical benefit rate is over 70% in the Phase 1 trial.
Worry ifEarly data shows a clinical benefit rate under 50% in the ongoing Phase 1 trial.
Why it matters: Positive results could support Kairos's goal to change treatment for lung cancer. This would validate ENV-105's effectiveness.
Supportive ifInterim results show no serious adverse events in patients treated with ENV-105.
Worry ifNew data reveals serious adverse events in patients treated with ENV-105.
Why it matters: This collaboration aims to enhance treatment options for prostate cancer. Success could expand Kairos's market reach.
Supportive ifThe clinical data from the collaboration is positive. It shows better results for prostate cancer patients.
Worry ifThe clinical data from the collaboration is negative. It shows no better results for patients.
Why it matters: The reverse stock split helps meet NYSE listing rules. This could affect investor trust.
Watch forThe stock price stays the same or goes up after the split. This shows good market response.
Also watch forThe stock price drops a lot after the split. This shows bad market response.